BAFF maintains T-cell survival by inducing OPN expression in B cells

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 129-137

  Ma, Ning ^a,b   He, Youdi ^c   Xiao, He ^a   Han, Gencheng ^a   Chen, Guojiang ^a   Wang, Yi ^a   Wang, Ke ^a   Hou, Chunmei ^a   Yang, Xiaomei ^a   Marrero, Bernadette ^d   Wang, Yujuan ^d   Shen, Beifen ^a   Li, Yan ^a   Wang, Renxi ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d NATIONAL EYE INSTITUTE   (United States)

Author keywords

BAFF; EAE; OPN; T cells

Indexed keywords

B CELL ACTIVATING FACTOR; CD23 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MYELIN; OSTEOPONTIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ALLERGIC ENCEPHALITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE;

BAFF; EAE; OPN; T CELLS;

ANIMALS; APOPTOSIS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NF-KAPPA B; OSTEOPONTIN; PEPTIDE FRAGMENTS; RECEPTORS, COMPLEMENT 3D; RECEPTORS, IGE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 84884695657     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.08.014     Document Type: Article

References (30)

1. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., Gery I., Lee Y.S., Egwuagu C.E. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711-718.
2. Boneparth A., Davidson A. B-cell activating factor targeted therapy and lupus. Arthritis Res. Ther. 2012, 14(Suppl. 4):S2.
3. Butzkueven H., Emery B., Cipriani T., Marriott M.P., Kilpatrick T.J. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 2006, 53:696-703.
4. Cantor H., Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 2009, 9:137-141.
5. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine; osteopontin; on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
6. Clemens M.J., van Venrooij W.J., van de Putte L.B.A. Apoptosis and autoimmunity. Cell Death Differ. 2000, 7:131-133.
7. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
8. Dillon S.R., Gross J.A., Ansell S.M., Novak A.J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 2006, 5:235-246.
9. Galicia G., Boulianne B., Pikor N., Martin A., Gommerman J.L. Secondary B cell receptor diversification is necessary for T cell mediated neuro-inflammation during experimental autoimmune encephalomyelitis. PLoS ONE 2013, 8:e61478.
10. Giovannetti A., Pierdominici M., Di Iorio A., Cianci R., Murdaca G., Puppo F., Pandolfi F., Paganelli R. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr. Pharm. Des. 2008, 14:253-268.
11. Gresle M.M., Shaw G., Jarrott B., Alexandrou E.N., Friedhuber A., Kilpatrick T.J., Butzkueven H. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2008, 86:3548-3555.
12. Handel A.E., Lincoln M.R., Ramagopalan S.V. Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. Eur. J. Clin. Invest. 2011, 41:1254-1258.
13. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 2007, 8:74-83.
14. Iglesias A., Bauer J., Litzenburger T., Schubart A., Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001, 36:220-234.
15. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H. Attenuated experimental autoimmune encephalomyelitis in Ets-1/osteopontin-deficient mice. J. Immunol. 2002, 168:2096-2099.
16. Kinnunen T., Chamberlain N., Morbach H., Cantaert T., Lynch M., Preston-Hurlburt P., Herold K.C., Hafler D.A., O'Connor K.C., Meffre E. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J. Clin. Invest. 2013, 123:2737-2741.
17. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., Kalled S.L., Hess D.M., Serafini B., Aloisi F., Wekerle H., Hohlfeld R., Meinl E. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 2005, 201:195-200.
18. Mackay F., Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 2009, 9:491-502.
19. Magliozzi R., Columba-Cabezas S., Serafini B., Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:11-23.
20. Mauri C., Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30:221-241.
21. Mitsdoerffer M., Kuchroo V., Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann. N. Y. Acad. Sci. 2013, 1283:57-66.
22. Patarea R., Wei F.Y., Singh P., Morasso M.I., Cantor H. Dysregulated expression of the T-cell cytokine Eta-1 in CD4-8-lymphocytes during the development of murine autoimmune diseases. J. Exp. Med. 1990, 172:1177-1183.
23. Pender M.P., Rist M.J. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001, 36:137-144.
24. Pua H.H., He Y.W. Autophagy and lymphocyte homeostasis. Curr. Top. Microbiol. Immunol. 2009, 335:85-105.
25. Rodgers J.M., Miller S.D. Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J. Biol. Med. 2012, 85:447-468.
26. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 2005, 17:282-289.
27. Stromnes I.M., Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1:1810-1819.
28. Tada S., Yasui T., Nakatsuji Y., Okuno T., Koda T., Mochizuki H., Sakoda S., Kikutani H. BAFF controls neural cell survival through BAFF receptor. PLoS ONE 2013, 8:e70924.
29. Van Parijs L., Peterson D.A., Abbas A.K. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998, 8:265-274.
30. Vincent F.B., Morand E.F., Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol. Cell. Biol. 2012, 90:293-303.